Amid revamp, U.S. FDA names acting head of generic drugs office

By Toni Clarke (Reuters) – The U.S. Food and Drug Administration has named Dr Kathleen Uhl acting director of its generic drugs division as it implements the biggest revamp of the department in more than a decade. Uhl replaces Dr Gregory Geba, who resigned abruptly last week after just eight months on the job, saying the reorganization will change the scope and responsibilities of the office in a way that no longer made his position attractive. …